May 25, 2016 7:24am
… Of patients suffering from hand problems due to scleroderma
CYTX’s U.S. FDA-approved P3 STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
The Bottom Line: Trial is ahead of schedule. Full trial data are expected to be available in mid-2017.
CYTX closed down -$0.03 to $2.93. CYTX is still in the midst of a rights offering - BUY